OHR Pharmaceuticals Selling Off As Feuerstein Calls Phase II A Failure
As Feuerstein explained, the report looks positive; the title even totes “positive” results. This left many investors wondering why shares were selling off out of the open.
The fifth paragraph is the important one, which shows that OHR’s treatment did not outperform the placebo on the main focus of the study.
In addition, the so-called positive results are not statistically significant, Feuerstein points out.
Shares of OHR Pharmaceuticals started selling off sharply when Feuerstein’s article was published, and are still dropping. The stock is at $9.87, over a 13 percent drop from Monday's close.
Latest Ratings for OHRP
|Oct 2016||H.C. Wainwright||Initiates Coverage On||Buy|
|Oct 2016||Brean Capital||Assumes||Hold|
|Aug 2016||Brean Capital||Downgrades||Buy||Hold|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.